Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAIROS – Early brief intensification by chemoimmunotherapy with FCR followed by FR and rituximab maintenance in treatment‑naive B‑CLL
2005-001502-11Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Roche. Primary endpoints: Complete remission rate and Best overall response rate. Started Jun 2005; status: completed.
02
Drugs
rituximabfludarabinecyclophosphamide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2005-001502-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001502-11.